Assesment of the Metabolomic Signature in COVID-19 Patients

Centre Hospitalier Universitaire de Nice150 enrolled

Overview

Metabolomics is the analysis of small molecules in a biological sample (cells, tissues or biological fluids). It can potentially detect very sensitively any change related to a pathology or exposure to a toxic agent. The analyses are fast, inexpensive and therefore applicable in routine, particularly in health care. Given the emergence of this new disease, COVID-19, there is a real need to better understand the pathophysiological mechanisms of SARS-CoV-2 infection. In this context, metabolomics could have a place and could lead to the development of interesting diagnostic or prognostic tools. The objective of this study is to identify, through the analysis of biological samples (blood and urine), whether there is a metabolomic signature in patients with COVID-19.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

150

Conditions

COVID 19

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patient over 18 years of age * affiliated to a social security scheme * consultant in the emergency department and/or being hospitalized for suspected SARS CoV infection * confirmation, after medical examination, of the need for a biological examination (this will negate the need for additional venipuncture) Exclusion criteria: * Patient who do not meet inclusion criteria * Person subject to a guardianship order * Opposition to the use of the data or samples (withdrawal of non-opposition) / Sponsor's or investigator's decision

Outcomes

Primary Outcomes

Identifying the metabolomic signature

To dentified a metabolomic profile using liquid chromatography combined with mass spectrometry (LC-MS) on the serum and urine of COVID-19 patients

Time frame: Enrollment

Secondary Outcomes

Identification of the metabolomic profile according to clinical severity.

Identification of the metabolomic profile of patients infected with SARS CoV 2 in the following subgroups: pauci-symptomatic patients, symptomatic patients without clinical severity criteria, and critically ill COVID-19 patients.